About Me
Conditions and Treatments
Conditions
- abdominal tumor
- aids-related lymphoma
- aids-related malignancies
- anemia
- blood cancer
- breast cancer
- colorectal cancer
- gastrointestinal cancer
- kaposi sarcoma
- lung cancer
- lung carcinoma
- lymphoma
- malignant mesothelioma
- mediastinal tumor
- mesothelioma
- non-small cell lung cancer
- platelet disorder
- small cell lung cancer
- solitary fibrous tumor
- thoracic cancer
- thymus cancer
Learn more about conditions we treat at NYU Langone:
Liver Cancer & Liver Metastases , Stomach Cancer , AIDS-Related Lymphoma , Acute Lymphoblastic Leukemia , Acute Myeloid Leukemia , Chronic Lymphocytic Leukemia , Chronic Myelogenous Leukemia , Cutaneous T-Cell Lymphoma , Hairy Cell Leukemia , Myelodysplastic Syndromes , Myeloproliferative Disorders , Non-Hodgkin Lymphoma , Breast Cancer , Male Breast Cancer , Colorectal Cancer , Small Intestine Cancer , Kaposi Sarcoma , Lung Cancer , Non-Small Cell Lung Cancer , Small Cell Lung Cancer , Hodgkin Lymphoma , Primary Central Nervous System Lymphoma , Malignant Mesothelioma , Soft Tissue SarcomaCredentials
Positions
- Clinical Associate Professor, Department of Medicine at NYU Grossman School of Medicine
Board Certifications
- American Board of Internal Medicine (Medical Oncology), 1987
- American Board of Internal Medicine - Internal Medicine, 1986
Education and Training
- Fellowship, Memorial Sloan Kettering Cancer Center, Hematology/Oncology, 1988
- MD from Johns Hopkins University, 1980
Is this your profile?
Edit profileInsurance Plans Accepted
This provider accepts the following insurance plans.
-
Aetna
- Aetna HMO
- Aetna Indemnity
- Aetna Medicare
- Aetna POS
- Aetna PPO/EPO
-
Blue Cross Blue Shield
- Empire BCBS Top Tier
-
Cigna
- Cigna EPO/POS
- Cigna PPO
-
Empire Blue Cross Blue Shield
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield MediBlue
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
-
GHI
- GHI CBP
-
HIP
- HIP Access I
- HIP Access II
- HIP Child Health
- HIP EPO/PPO
- HIP HMO
- HIP Medicare
- HIP POS
-
Local 1199
- Local 1199 PPO
-
MultiPlan/PHCS
- MultiPlan/PHCS PPO
-
Oxford
- Oxford Freedom
- Oxford Liberty
- Oxford Medicare
-
UHC
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare Medicare
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
-
UPN
- UPN Elite
Alec S. Goldenberg, MD does not accept insurance.
Locations and Appointments
Manhattan Medical Oncology, PLLC
157 East 32nd St, New York, NY 10016
Research My Research
Interests
hematologic abnormalities, Early and advanced cancer types , mycobacterial infections, hematologic growth factors
Research Interests Timeline
These focus areas and their associated publications are derived from PubMed and the MeSH term library.
*
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.
Publications
-
Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Wierda, William G.; Claudia Barrientos, Jacqueline; Lamanna, Nicole; Goldenberg, Alec; Isufi, Iris; Tuscano, Joseph M.; Subbiah, Suki; Weihe, Elizabeth Kristine; Ianopulos, Xen; Breitmeyer, James Bradley; Hsu, Frank J.; Wang, Michael; Jamieson, Catriona Hm; Kipps, Thomas J.Journal of clinical oncology. 2020; 38(15):
-
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Wierda, William G.; Barrientos, Jacqueline C.; Lamanna, Nicole; Goldenberg, Alec; Isufi, Iris; Tuscano, Joseph; Subbiah, Suki; Koff, Jean L.; Leslie, Lori A.; Chung, Gina G.; Weihe, Elizabeth K.; Ianopulos, Xen; Breitmeyer, James B.; Hsu, Frank J.; Wang, Michael; Jamieson, Catriona; Kipps, Thomas J.Blood. 2020; 136:
-
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL
Choi, Michael Y.; Ghia, Emanuela M.; Siddiqi, Tanya; Wierda, William G.; Lee, Hun Ju; Barrientos, Jacqueline C.; Lamanna, Nicole; Goldenberg, Alec; Tzachanis, Dimitrios; Reid, Erin G.; Weihe, Elizabeth K.; Rassenti, Laura Z.; Isufi, Iris; Bieler, Stewart; Ianopulos, Xen; Breitmeyer, James B.; Jamieson, Catriona; Kipps, Thomas J.Blood. 2019; 134: